WallStreetZenWallStreetZen

NASDAQ: LPCN
Lipocine Inc Stock Forecast, Predictions & Price Target

OverviewForecast
EarningsRevenueDividendOwnership

Analyst price target for LPCN

Based on 1 analyst offering 12 month price targets for Lipocine Inc

Min Forecast
$8.00+156.82%
Avg Forecast
$8.00+156.82%
Max Forecast
$8.00+156.82%

Should I buy or sell LPCN stock?

Based on 1 analyst offering ratings for Lipocine Inc.

Buy
Strong Buy
0 analysts 0%
Buy
1 analysts 100%
Hold
0 analysts 0%
Sell
0 analysts 0%
Strong Sell
0 analysts 0%

Be the first to know when Wall Street analysts revise their LPCN stock forecasts and price targets.

LPCN stock forecasts by analyst

Analyst / FirmRatingActionPrice TargetUpside/DownsideDateAnalyst Color
lockedlocked$00.00+00.00%2025-06-10

1 of 1

Forecast return on equity

Is LPCN forecast to generate an efficient return?

Company
-46.82%
Industry
29.26%
Market
56.76%
LPCN's Return on Equity is... subscribe to Premium to read more.
Forecast High Return on Equity Forecast

Forecast return on assets

Is LPCN forecast to generate an efficient return on assets?

Company
-43.85%
Industry
10.9%
LPCN is forecast to generate... subscribe to Premium to read more.
Forecast Return on Assets vs Industry Forecast

LPCN earnings per share forecast

What is LPCN's earnings per share in the next 2 years based on estimates from 1 analyst?

Avg 1 year Forecast
-$1.70
Avg 2 year Forecast
-$1.68

LPCN revenue forecast

What is LPCN's revenue in the next 2 years based on estimates from 1 analyst?

Avg 1 year Forecast
$3.9M+7.22%
Avg 2 year Forecast
$4.0M+8.85%
LPCN's revenue is forecast to... subscribe to Premium to read more.
Forecast High Revenue Growth Forecast

LPCN revenue growth forecast

How is LPCN forecast to perform vs Biotechnology companies and vs the US market?

Company
7.22%
Industry
3,065.21%
Market
55.62%
LPCN's revenues are forecast to... subscribe to Premium to read more.
Forecast Revenue Growth vs Industry Forecast
LPCN's revenues are forecast to... subscribe to Premium to read more.
Forecast Revenue Growth vs Market Forecast

LPCN vs Biotech Stocks

TickerPricePrice TargetUp/downsideConsensus
LPCN$3.12$8.00+156.82%Buy
NRXS$2.29N/AN/A
LPTX$0.41$5.50+1,241.46%Buy
PMN$0.52$4.50+765.38%Strong Buy
XFOR$2.82$48.50+1,619.86%Strong Buy
View Top Biotech Stocks

Lipocine Stock Forecast FAQ

Is Lipocine Stock a good buy in 2025, according to Wall Street analysts?

The consensus among 1 Wall Street analyst covering (NASDAQ: LPCN) stock is to Buy LPCN stock.

Out of 1 analyst, 0 (0%) are recommending LPCN as a Strong Buy, 1 (100%) are recommending LPCN as a Buy, 0 (0%) are recommending LPCN as a Hold, 0 (0%) are recommending LPCN as a Sell, and 0 (0%) are recommending LPCN as a Strong Sell.

If you're new to stock investing, here's how to buy Lipocine stock.

What is LPCN's earnings growth forecast for 2025-2026?

(NASDAQ: LPCN) Lipocine's forecast annual earnings growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast earnings growth rate of 22.32%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 57.17%.

Lipocine's earnings in 2025 is -$5,370,142.On average, 1 Wall Street analyst forecast LPCN's earnings for 2025 to be -$9,095,605, with the lowest LPCN earnings forecast at -$9,095,605, and the highest LPCN earnings forecast at -$9,095,605.

In 2026, LPCN is forecast to generate -$8,988,598 in earnings, with the lowest earnings forecast at -$8,988,598 and the highest earnings forecast at -$8,988,598.

What is LPCN's revenue growth forecast for 2025-2026?

(NASDAQ: LPCN) Lipocine's forecast annual revenue growth rate of 7.22% is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 3,065.21%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 55.62%.

Lipocine's revenue in 2025 is $3,674,835.On average, 1 Wall Street analysts forecast LPCN's revenue for 2025 to be $21,080,403, with the lowest LPCN revenue forecast at $21,080,403, and the highest LPCN revenue forecast at $21,080,403.

In 2026, LPCN is forecast to generate $21,401,424 in revenue, with the lowest revenue forecast at $21,401,424 and the highest revenue forecast at $21,401,424.

What is LPCN's forecast return on assets (ROA) for 2025-2026?

(NASDAQ: LPCN) forecast ROA is -43.85%, which is lower than the forecast US Biotechnology industry average of 10.9%.

What is LPCN's Price Target?

According to 1 Wall Street analyst that have issued a 1 year LPCN price target, the average LPCN price target is $8.00, with the highest LPCN stock price forecast at $8.00 and the lowest LPCN stock price forecast at $8.00.

The Wall Street analyst predicted that Lipocine's share price could reach $8.00 by Jun 10, 2026. The average Lipocine stock price prediction forecasts a potential upside of 156.82% from the current LPCN share price of $3.12.

What is LPCN's Earnings Per Share (EPS) forecast for 2025-2026?

(NASDAQ: LPCN) Lipocine's current Earnings Per Share (EPS) is -$1.00. On average, analysts forecast that LPCN's EPS will be -$1.70 for 2025, with the lowest EPS forecast at -$1.70, and the highest EPS forecast at -$1.70. In 2026, LPCN's EPS is forecast to hit -$1.68 (min: -$1.68, max: -$1.68).

What is LPCN's forecast return on equity (ROE) for 2025-2026?

(NASDAQ: LPCN) forecast ROE is -46.82%, which is considered weak.
©2025 WallStreetZen
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletter
Stock Tools
Top Performing AnalystsStock ScreenerStock ForecastTrending StocksStrong Buy StocksHighest Earnings StocksBest Dividend Paying StocksStatisticsStock Market SectorsStock Market IndustriesHow to Buy Stocks Online
Stock Ideas
Buy The DipBiggest Stock Gainers TodayBiggest Stock Losers Today52 Week High Stocks52 Week Low StocksMost Active Stocks TodayMost Undervalued StocksBest Penny Stocks to Buy NowBest Stocks Under $5Best Stocks Under $10
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.